Baxalta-Coherus Enbrel biosimilar succeeds in late-stage study

January 11, 2016 12:38 PM

27 0

Baxalta Inc and Coherus Biosciences Inc said their experimental biosimilar of Amgen Inc's arthritis drug Enbrel met the main goal in a late-stage study.

The drug, CHS-0214, was found to be as effective as Enbrel in rheumatoid arthritis patients, with no clinically meaningful differences in terms of its safety, the companies said on Monday.

Read more

To category page